CAUTION: Investigational Device, limited by Federal U.S. law to investigational use. To be used by Qualified investigators only
The Solution
TegoSens is developing a revolutionary micro-radar device that is low cost, easy to use, and provides a specific measure of lung fluid and other supporting measurements as an early indication of fluid build-up in HF patients
Portable
Easy to use
Non-invasive
Low cost
Early & timely fluid retention detection
Specific fluid measure
Point of care & at home use ability
Remote patient monitoring capability
Point of care solution
Radio frequency signals are sent and received via a patch on the patient
These signals are processed and fluid level in lungs are displayed on the monitor
At home solution
Data is sent from the device to the Smart Phone App
Data is transmitted from the Smart Phone App to the cloud for storage, monitoring and analytics providing actionable data
Measurements sent to the clinician driving individualized medical therapies
Early identification of Hemodynamic Congestion
“Most hospitalizations for acute heart failure (HF) are related to clinical congestion rather than to low cardiac output. Patients frequently develop “hemodynamic congestion” several days to weeks before the onset of symptoms and signs of clinical congestion. By the time symptoms and signs are evident, patients generally require hospitalization.”
“Identification of hemodynamic congestion, before clinical manifestations appear, may potentially prevent hospitalization and slow the progression of HF by allowing life-saving interventions to be implemented sooner.”
Source: Mihai Gheorghiade, David D. Shin, Tarita O. Thomas, Filippo Brandimarte, Gregg C. Fonarow, William T. Abraham; Congestion Is an Important Diagnostic and Therapeutic Target in Heart Failure - S12 Vol. 7 Suppl. 1 2006 Reviews in Cardiovascular Medicine
Remote patient management
When fluid build-up is caught early on, medications can be adjusted with on-staff clinicians. The plan is to allow patients who require additional care to be directed to outpatient settings for the administration of diuretics reducing fluid build-up and to avoid costly readmissions.
Effective management of HF must start with early diagnosis and include ongoing support delivered outside of the hospital settings.
This disruptive technology accelerates market extension and growth into remote patient management, adding value in Heart Failure patient care continuum. It allows for titrating of medications and precision medication management of these patients with the goal of preventing preventing readmissions and life-threatening complications.
Market extending technology platform, in development, will enable data driven subscription solutions for telehealth. This technology provides offline data analysis and predictive modeling capability.